Anthrax lethal factor (LF) mediated block of the anthrax protective antigen (PA) ion channel: effect of ionic strength and voltage

Biochemistry
Tobias NeumeyerR Benz

Abstract

The anthrax toxin complex consists of three different molecules, protective antigen (PA), lethal factor (LF), and edema factor (EF). The activated form of PA, PA(63), forms heptamers that insert at low pH in biological membranes forming ion channels and that are necessary to translocate EF and LF in the cell cytosol. LF and EF are intracellular active enzymes that inhibit the host immune system promoting bacterial outgrowth. Here, PA(63) was reconstituted into artificial lipid bilayer membranes and formed ion-permeable channels. The heptameric PA(63) channel contains a binding site for LF on the cis side of the channel. Full-size LF was found to block the PA(63) channel in a dose- and ionic-strength-dependent way with half-saturation constants in the nanomolar concentration range. The binding curves suggest a 1:1 relationship between (PA(63))(7) and bound LF that blocks the channel. The presence of a His(6) tag at the N-terminal end of LF strongly increases the affinity of LF toward the PA(63) channel, indicating that the interaction between LF and the PA(63) channel occurs at the N terminus of the enzyme. The LF-mediated block of the PA(63)-induced membrane conductance is highly asymmetric with respect to the sign of the appli...Continue Reading

References

Jan 1, 1987·The Journal of Membrane Biology·R BenzG H Vos-Scheperkeuter
Sep 9, 1999·The New England Journal of Medicine·T C DixonP C Hanna
Dec 13, 2000·The Journal of Biological Chemistry·B R SellmanR J Collier
Jan 29, 2003·The Journal of Cell Biology·Laurence AbramiF Gisou van der Goot
Oct 23, 2003·Annual Review of Cell and Developmental Biology·R John Collier, John A T Young
Oct 13, 2004·The Journal of Infectious Diseases·Andrew W ArtensteinJhung W Jhung
Aug 10, 2005·The Journal of Biological Chemistry·Kelly M HalversonJohn J Kasianowicz

❮ Previous
Next ❯

Citations

Jun 1, 2011·The Journal of General Physiology·Daniel BasilioAlan Finkelstein
Nov 1, 2006·Antimicrobial Agents and Chemotherapy·Marina V BackerJoseph M Backer
Sep 5, 2006·Eukaryotic Cell·Godfrey LiskSanjay A Desai
Mar 6, 2007·Annual Review of Biochemistry·John A T Young, R John Collier
Aug 21, 2013·The Journal of Chemical Physics·Brian J NabloJohn J Kasianowicz
Aug 19, 2015·Biochimica Et Biophysica Acta·O KnappM R Popoff
Aug 27, 2015·Biochimica Et Biophysica Acta·Marco PirazziniCesare Montecucco
Jul 24, 2013·Biophysical Chemistry·Marta MarchiorettoGregor Anderluh
Aug 12, 2009·Molecular Aspects of Medicine·Fiorella Tonello, Cesare Montecucco
Oct 10, 2006·Journal of Molecular Biology·Christian SchlebergerGeorg E Schulz
Jan 11, 2007·Molecular Immunology·Sebastian C J SteinigerKim D Janda
Jul 4, 2008·Clinical and Vaccine Immunology : CVI·Sarah C Taft, Alison A Weiss
Sep 7, 2006·The Journal of Biological Chemistry·Tobias NeumeyerRoland Benz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.